Our mission is to deliver best-in-class therapeutics to patients with sight threatening diseases
Ocugen is a rapidly growing, clinical stage biopharmaceutical company dedicated to developing innovative therapies for underserved areas of ophthalmology, including rare eye disorders and sight-threatening diseases. To accomplish its goal, the Company is broadly pursuing novel biologics to treat degenerative and neovascular diseases of the eye, as well as re-inventing new applications for currently available small-molecule therapeutics that could make a significant difference for patients. Ocugen is aggressively pursuing conditions such as ocular graft versus host disease (OCU300), dry eye (OCU310), retinitis pigmentosa (OCU100) and wet age-related macular degeneration (OCU200).
Latest Press Releases
Ocugen, Inc. today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference.
FDA Decision Marks First Orphan Drug Designation for Treatment of oGVHD in the U.S.